Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Clinical trial NCT07523737 · RECRUITING

Trial details

NCT number: NCT07523737
Sponsor: Beijing Tongren Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Central Nervous System Lymphoma (PCNSL)Diffuse Large B Cell Lymphoma (DLBCL)

Start date: 2026-04-01
Primary completion: 2028-03-31
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.